CI
Cypre Inc. develops proprietary hydrogel-based 3D in vitro tumor microenvironment models that enable pharmaceutical and biotech companies to evaluate drug efficacy and mechanisms of action. These models address the challenge of drug resistance in cancer treatment by providing translatable insights for therapeutic innovation.
Updated 4 months ago
Funding
$875K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- Cypre Inc. develops proprietary hydrogel-based 3D in vitro tumor microenvironment models that enable pharmaceutical and biotech companies to evaluate drug efficacy and mechanisms of action. These models address the challenge of drug resistance in cancer treatment by providing translatable insights for therapeutic innovation.